Correlation of HIF-1α expression in DCIS lesions of <i>BRCA1</i>, <i>BRCA2</i> and non-<i>BRCA</i> mutation carriers with age, grade, ER, PR, HER2, CAIX and Glut-1 expression in these lesions.

<p>Correlation of HIF-1α expression in DCIS lesions of <i>BRCA1</i>, <i>BRCA2</i> and non-<i>BRCA</i> mutation carriers with age, grade, ER, PR, HER2, CAIX and Glut-1 expression in these lesions.</p

Clinicopathological characteristics and expression of ER, PR, HER2, HIF-1α, CAIX and Glut-1 in DCIS lesions of <i>BRCA1</i>, <i>BRCA2</i> and non-<i>BRCA</i> mutation carriers.

<p>Clinicopathological characteristics and expression of ER, PR, HER2, HIF-1α, CAIX and Glut-1 in DCIS lesions of <i>BRCA1</i>, <i>BRCA2</i> and non-<i>BRCA</i> mutation carriers.</p

Immunohistochemical staining of HIF-1α, CAIX and Glut-1 in normal breast tissue (A, D and G), DCIS (B, E and H) and concomitant invasive cancer (C, F and I) of a <i>BRCA1</i> mutation carrier.

<p>Immunohistochemical staining of HIF-1α, CAIX and Glut-1 in normal breast tissue (A, D and G), DCIS (B, E and H) and concomitant invasive cancer (C, F and I) of a <i>BRCA1</i> mutation carrier.</p

Correlation of HIF-1α, CAIX and Glut-1 between invasive and DCIS lesions of <i>BRCA1</i>, <i>BRCA2</i> and non-<i>BRCA</i> mutation carriers.

<p>Correlation of HIF-1α, CAIX and Glut-1 between invasive and DCIS lesions of <i>BRCA1</i>, <i>BRCA2</i> and non-<i>BRCA</i> mutation carriers.</p

Clinicopathological characteristics and expression of ER, PR, HER2, HIF-1α, CAIX and Glut-1 in DCIS and accompanying invasive lesions of <i>BRCA1</i>, <i>BRCA2</i> and non-<i>BRCA</i> mutation carriers.

<p>Clinicopathological characteristics and expression of ER, PR, HER2, HIF-1α, CAIX and Glut-1 in DCIS and accompanying invasive lesions of <i>BRCA1</i>, <i>BRCA2</i> and non-<i>BRCA</i> mutation carriers.</p

Characteristics breast cancer patients.

<p>Characteristics breast cancer patients.</p

Validation anti-human FR-β specificity and immunoreactivity.

<p><i>A</i>: Strong staining was appreciated in the placental villous stroma known to express FR-β, validating anti human FR-β binding specificity and immunoreactivity <i>B</i>: Absent staining was shown after staining with the secondary antibody only. Co-expression of the <i>C</i>: anti-CD68 stain and <i>D</i>: FR-β in activated macrophages in a diverticulitis sample validated anti-human FR-β specificity and immunoreactivity.</p

Characteristics ovarian cancer patients.

<p>Characteristics ovarian cancer patients.</p

FR-β expression in representative samples.

<p><i>A</i>: weak expression (staining intensity 1). <i>B</i>: moderate expression (staining intensity 2). <i>C</i>: strong expression (staining intensity 3).</p